Indivior PLC/ GB00BN4HT335 /
2024-05-16 9:17:00 AM | Chg. -6.00 | Volume | Bid9:20:56 AM | Ask9:17:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
1,394.00GBX | -0.43% | 810 Turnover(GBP): 11,308.5600 |
1,387.00Bid Size: 162 | 1,394.00Ask Size: 342 | 1.89 bill.GBP | - | - |
GlobeNewswire
04-18
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
04-11
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18,...
GlobeNewswire
04-03
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Mod...
GlobeNewswire
03-05
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
01-31
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
GlobeNewswire
2023-11-23
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on Novem...
Newsfile Corp
2023-10-31
Pharma and Biotech Business Development Leaders to Discuss Psychedelics Partnering at Wonderland
GlobeNewswire
2023-09-06
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference